ANTI-SIRPa ANTIBODY
The object of the present invention is to provide an anti-SIRPα antibody that can be used as a tumor agent and an anti-tumor agent comprising the antibody as an active ingredient. The present invention is an antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47, t...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | NAKAMURA Kensuke SUE Mayumi YOSHIMURA Chigusa MATOZAKI Takashi |
| description | The object of the present invention is to provide an anti-SIRPα antibody that can be used as a tumor agent and an anti-tumor agent comprising the antibody as an active ingredient. The present invention is an antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47, the antibody comprising: (a) a light chain CDRL1 consisting of an amino acid sequence set forth in SEQ ID NO: 1; (b) a light chain CDRL2 consisting of an amino acid sequence set forth in SEQ ID NO: 2; (c) a light chain CDRL3 consisting of an amino acid sequence set forth in SEQ ID NO: 3; (d) a heavy chain CDRH1 consisting of an amino acid sequence set forth in SEQ ID NO: 4; (e) a heavy chain CDRH2 consisting of an amino acid sequence set forth in SEQ ID NO: 5; and (f) a heavy chain CDRH3 consisting of an amino acid sequence set forth in SEQ ID NO: 6, wherein a heavy chain constant region is a heavy chain constant region of human IgG4, and phenylalanine at position 234, as numbered according to the EU index as in Kabat et al., is substituted by alanine, leucine at position 235 is substituted by alanine, and serine at position 228 is substituted by proline. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_SG11202012338QA</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>SG11202012338QA</sourcerecordid><originalsourceid>FETCH-epo_espacenet_SG11202012338QA3</originalsourceid><addsrcrecordid>eNrjZBB29Avx1A32DApIVAAxnfxdInkYWNMSc4pTeaE0N4OKm2uIs4duakF-fGpxQWJyal5qSXywu6GhkYGRgaGRsbFFoKMxkcoAGx8f1A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ANTI-SIRPa ANTIBODY</title><source>esp@cenet</source><creator>NAKAMURA Kensuke ; SUE Mayumi ; YOSHIMURA Chigusa ; MATOZAKI Takashi</creator><creatorcontrib>NAKAMURA Kensuke ; SUE Mayumi ; YOSHIMURA Chigusa ; MATOZAKI Takashi</creatorcontrib><description>The object of the present invention is to provide an anti-SIRPα antibody that can be used as a tumor agent and an anti-tumor agent comprising the antibody as an active ingredient. The present invention is an antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47, the antibody comprising: (a) a light chain CDRL1 consisting of an amino acid sequence set forth in SEQ ID NO: 1; (b) a light chain CDRL2 consisting of an amino acid sequence set forth in SEQ ID NO: 2; (c) a light chain CDRL3 consisting of an amino acid sequence set forth in SEQ ID NO: 3; (d) a heavy chain CDRH1 consisting of an amino acid sequence set forth in SEQ ID NO: 4; (e) a heavy chain CDRH2 consisting of an amino acid sequence set forth in SEQ ID NO: 5; and (f) a heavy chain CDRH3 consisting of an amino acid sequence set forth in SEQ ID NO: 6, wherein a heavy chain constant region is a heavy chain constant region of human IgG4, and phenylalanine at position 234, as numbered according to the EU index as in Kabat et al., is substituted by alanine, leucine at position 235 is substituted by alanine, and serine at position 228 is substituted by proline.</description><language>eng</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210128&DB=EPODOC&CC=SG&NR=11202012338QA$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210128&DB=EPODOC&CC=SG&NR=11202012338QA$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>NAKAMURA Kensuke</creatorcontrib><creatorcontrib>SUE Mayumi</creatorcontrib><creatorcontrib>YOSHIMURA Chigusa</creatorcontrib><creatorcontrib>MATOZAKI Takashi</creatorcontrib><title>ANTI-SIRPa ANTIBODY</title><description>The object of the present invention is to provide an anti-SIRPα antibody that can be used as a tumor agent and an anti-tumor agent comprising the antibody as an active ingredient. The present invention is an antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47, the antibody comprising: (a) a light chain CDRL1 consisting of an amino acid sequence set forth in SEQ ID NO: 1; (b) a light chain CDRL2 consisting of an amino acid sequence set forth in SEQ ID NO: 2; (c) a light chain CDRL3 consisting of an amino acid sequence set forth in SEQ ID NO: 3; (d) a heavy chain CDRH1 consisting of an amino acid sequence set forth in SEQ ID NO: 4; (e) a heavy chain CDRH2 consisting of an amino acid sequence set forth in SEQ ID NO: 5; and (f) a heavy chain CDRH3 consisting of an amino acid sequence set forth in SEQ ID NO: 6, wherein a heavy chain constant region is a heavy chain constant region of human IgG4, and phenylalanine at position 234, as numbered according to the EU index as in Kabat et al., is substituted by alanine, leucine at position 235 is substituted by alanine, and serine at position 228 is substituted by proline.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZBB29Avx1A32DApIVAAxnfxdInkYWNMSc4pTeaE0N4OKm2uIs4duakF-fGpxQWJyal5qSXywu6GhkYGRgaGRsbFFoKMxkcoAGx8f1A</recordid><startdate>20210128</startdate><enddate>20210128</enddate><creator>NAKAMURA Kensuke</creator><creator>SUE Mayumi</creator><creator>YOSHIMURA Chigusa</creator><creator>MATOZAKI Takashi</creator><scope>EVB</scope></search><sort><creationdate>20210128</creationdate><title>ANTI-SIRPa ANTIBODY</title><author>NAKAMURA Kensuke ; SUE Mayumi ; YOSHIMURA Chigusa ; MATOZAKI Takashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_SG11202012338QA3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2021</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>NAKAMURA Kensuke</creatorcontrib><creatorcontrib>SUE Mayumi</creatorcontrib><creatorcontrib>YOSHIMURA Chigusa</creatorcontrib><creatorcontrib>MATOZAKI Takashi</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>NAKAMURA Kensuke</au><au>SUE Mayumi</au><au>YOSHIMURA Chigusa</au><au>MATOZAKI Takashi</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ANTI-SIRPa ANTIBODY</title><date>2021-01-28</date><risdate>2021</risdate><abstract>The object of the present invention is to provide an anti-SIRPα antibody that can be used as a tumor agent and an anti-tumor agent comprising the antibody as an active ingredient. The present invention is an antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47, the antibody comprising: (a) a light chain CDRL1 consisting of an amino acid sequence set forth in SEQ ID NO: 1; (b) a light chain CDRL2 consisting of an amino acid sequence set forth in SEQ ID NO: 2; (c) a light chain CDRL3 consisting of an amino acid sequence set forth in SEQ ID NO: 3; (d) a heavy chain CDRH1 consisting of an amino acid sequence set forth in SEQ ID NO: 4; (e) a heavy chain CDRH2 consisting of an amino acid sequence set forth in SEQ ID NO: 5; and (f) a heavy chain CDRH3 consisting of an amino acid sequence set forth in SEQ ID NO: 6, wherein a heavy chain constant region is a heavy chain constant region of human IgG4, and phenylalanine at position 234, as numbered according to the EU index as in Kabat et al., is substituted by alanine, leucine at position 235 is substituted by alanine, and serine at position 228 is substituted by proline.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_SG11202012338QA |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
| title | ANTI-SIRPa ANTIBODY |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T12%3A21%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=NAKAMURA%20Kensuke&rft.date=2021-01-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ESG11202012338QA%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |